Navigation Links
SK Life Sciences has Licensed Pristima
Date:8/5/2009

Xybion Medical Systems, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion Medical Systems, a world leader in toxicology and pathology data management solutions and the developer of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

After extensive research and evaluation of the products on the market, SKLSI selected Xybion's Pristima to manage its general toxicology data as well as licensing Xybion's Standard Validation Package and contracting Xybion to perform the full suite of installation, training and validation execution services. Additionally, SKLSI has contracted to have Xybion's professional services team perform all of the hardware installation, third-party software installation and all other IT services related to Pristima.

Dr. Pradip Banerjee, Xybion's CEO, stated that "we are proud to add SK Life Science, Inc., another leading global research and development company to our growing community. We are tremendously satisfied that SKLSI has acknowledged Pristima to be the most powerful system on the market. Pristima is designed to account for all types of toxicology studies and is specifically well-suited to collect, manage and summarize data for global pharmaceutical and chemical companies as well as contract research organizations."

Dr. Hong Wook Kim, Director, Non-clinical Development of SK Life Science, Inc., remarked that "SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects."

About SK Life Sciences - SK Life Science, Inc. (http://pharma.sk.com/english), US subsidiary of SK Holdings, Co., Ltd., one of the largest conglomerate and the leading energy and chemical company in Korea, has been engaged in the innovative discovery and development of novel therapeutic compounds in the field of neuroscience in order to treat CNS disorders including epilepsy, depression, anxiety, schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In addition to the CNS area of research, SK Life Science is working on the discovery and development of novel therapeutic compounds for the treatment of metabolic diseases.

About Xybion Medical Systems - Xybion (www.xybion.com) is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to the Pristima Data Management suite, Xybion provides professional services, consulting, training and validation activities to clients throughout the world.

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2711764.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Closing of Public Offering
2. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
3. Caliper Life Sciences Reports Second Quarter 2009 Results
4. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
5. Neurocrine Biosciences Reports Second Quarter 2009 Results
6. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
7. Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
8. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
9. Human Genome Sciences Announces Pricing of Public Offering of Common Stock
10. Human Genome Sciences Announces Proposed Public Offering of Common Stock
11. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):